Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy

导出原文传递

翻译打印收藏纠错

作者： Verstovsek, Srdan ^[1] ; Harrison, Claire N. ^[2] ; Kiladjian, Jean-Jacques ^[3] ; Miller, Carole ^[4] ; Naim, Ahmad B. ^[5] ; Paranagama, Dilan C. ^[6] ; Habr, Dany ^[7] ; Vannucchi, Alessandro M.

作者单位： St Agnes Canc Inst, Baltimore, MD USA ^[1] Incyte Corp, Wilmington, DE USA ^[2] Guys & St Thomas NHS Fdn Trust, London, England ^[3] Hop St Louis, AP HP, INSERM, Ctr Invest Clin INSERM CIC 1427, Paris, France ^[4] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA ^[5] Novartis Pharmaceut, E Hanover, NJ USA ^[6] AOU Careggi, CRIMM Ctr Res & Innovat Myeloproliferat Neoplasms, Florence, Italy ^[7]

关键词 Iron deficiency JAK2 Janus kinase 2 Polycythemia vera Ruxolitinib

发布时间 2017-11-22

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交

浏览1

Leukemia Research

2017年56卷

52-59页

相似文献

中文期刊
外文期刊
学位论文
会议论文

检索历史清除

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy

Leukemia Research

相似文献

Leukemia Research

相关期刊

参考文献：
指定格式：	NoteExpress EndNote RefWorks NoteFirst

检索历史 清除

Markers of iron deficiency in patients with polycythemia vera receiving ruxolitinib or best available therapy

Leukemia Research

相似文献

Leukemia Research

相关期刊

检索历史清除